Non-Integrating Viral Vector With Episomal Gene Expression Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current viral vector systems face challenges such as unpredictable gene integration sites, long-term expression leading to potential toxicity, and the need for repeated treatments due to lack of controlled transient expression.
Innovation Solution
A non-integrating, episomally replicating viral delivery system using lentiviral vectors with a defective integrase gene and heterologous viral episomal origins of replication, driven by inducible promoters, allowing precise regulation of gene expression and transient delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If chromosomal integration is used for stable expression, then long-term gene expression is achieved, but unpredictable integration sites and potential toxicity occur
Solution Approach 1:
The patent segments the viral vector system into two separate components: (1) a lentiviral vector that delivers the therapeutic gene without integration capability (defective integrase), and (2) a separate episomal replication origin system (from papillomavirus or herpesvirus) that enables controlled DNA replication. This segmentation allows the therapeutic gene to be expressed transiently without the harmful effects of chromosomal integration, resolving the contradiction between long-term expression and off-target toxicity.
Solution Approach 2:
The patent introduces an intermediary episomal replication system (papillomavirus E1/E2 proteins or herpesvirus EBNA-1) that mediates between the lentiviral delivery mechanism and the host cell genome. This intermediary allows the vector DNA to replicate and maintain itself as an episome without integrating into chromosomal DNA, thereby achieving sustained gene expression while avoiding the harmful effects of random integration.
2Object-affected harmful factors
If non-integrating plasmid vectors are used, then chromosomal integration is avoided, but expression is lost due to plasmid decay
Solution Approach 1:
The patent applies preliminary action by incorporating an episomal replication origin and associated initiator proteins into the vector design before delivery. This preliminary configuration enables the vector DNA to autonomously replicate and maintain itself as an episome in the host cell, preventing plasmid decay and loss of expression. The replication machinery is pre-assembled within the vector construct, ensuring sustained expression without requiring chromosomal integration.
3Stability of the object's composition
If integrating viral vectors are used, then permanent gene maintenance is achieved, but repeated treatments are required due to immune responses
Solution Approach 1:
The patent applies dynamics by making the gene expression system controllable and adjustable rather than permanent. The episomal replication system can be induced or suppressed as needed, allowing the expression level and duration to be dynamically regulated. This dynamic control enables the therapeutic effect to be maintained through controlled transient expression cycles, reducing the need for repeated treatments while avoiding the limitations of permanent integration.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates generally to non-integrating viral delivery system and methods of using the same. The viral delivery systems includes a viral carrier, a heterologous viral episomal origin of replication, a sequence encoding at least one initiator protein specific for the heterologous viral episomal origin of replication, and at least one gene, shRNA, siRNA, miRNA, or other gene-silencing RNA of interest. In certain embodiments, the disclosed system can be used for gene therapy.